PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

被引：0
作者：
Liu, S. -Y. M. [1 ,2 ]
Deng, J. -Y. [3 ]
Yan, H-H. [3 ]
Yang, M. -Y. [3 ]
Xu, C. -R. [3 ]
Zheng, M. -Y. [3 ]
Gan, B. [3 ]
Zhang, X. -C. [3 ]
Tu, H-Y. [3 ]
Yang, J. -J. [3 ]
Chen, H. -J. [3 ]
Wang, B. -C. [3 ]
Li, Y. [1 ,4 ]
Zhou, Q. [3 ]
Wu, Y. -L. [3 ]
机构：
[1] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China
[2] Chinese Thorac Oncol Grp CTONG, Guangzhou, Peoples R China
[3] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[4] Jinan Univ, Inst Hematol, Sch Med, Key Lab Regenerat Med,Minist Educ, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
non-small cell lung cancer; pembrolizumab; sintilimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-07
引用
收藏
页码：S319 / S320
页数：2
相关论文
共 50 条
  • [41] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
  • [42] Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab
    Elegbede, A.
    Cheung, W. Y.
    Gibson, A.
    Box, A.
    Bebb, G.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S336 - S337
  • [43] Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
    Marmarelis, M. E.
    Mathew, D.
    Bauml, J. M.
    Hwang, W. -T.
    Zhang, J.
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Zhang, N.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A. J.
    Wherry, E. J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S122 - S123
  • [44] Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line
    Zhao, Yue
    Mao, Yousheng
    He, Jie
    Gao, Shugeng
    Zhang, Zhirong
    Ding, Ningning
    Xue, Qi
    Gao, Yushun
    Wang, Dali
    Zhao, Jun
    Tan, Fengwei
    Yuan, Ligong
    Li, Feng
    Wang, Shuaibo
    Yang, Lin
    CLINICAL LUNG CANCER, 2021, 22 (02) : E201 - E210
  • [45] PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis
    Abdel-Rahman, Omar
    IMMUNOTHERAPY, 2016, 8 (09) : 1081 - 1090
  • [46] Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%
    Lopes, G.
    Wu, Y.
    Kudaba, I.
    Kowalski, D.
    Cho, B.
    Turna, H.
    De Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K.
    Bondarenko, I.
    Kubota, K.
    Lubiniecki, G.
    Zhang, J.
    Kush, D.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S152
  • [47] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Incorvaia, Lorena
    Fanale, Daniele
    Badalamenti, Giuseppe
    Barraco, Nadia
    Bono, Marco
    Corsini, Lidia Rita
    Galvano, Antonio
    Gristina, Valerio
    Listi, Angela
    Vieni, Salvatore
    Gori, Stefania
    Bazan, Viviana
    Russo, Antonio
    ADVANCES IN THERAPY, 2019, 36 (10) : 2600 - 2617
  • [48] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
    Wu, Y.
    Zhang, L.
    Fan, Y.
    Zhou, J.
    Zhang, L.
    Zhou, Q.
    Li, W.
    Hu, C.
    Chen, G.
    Zhang, X.
    Zhou, C.
    Dang, T.
    Penrod, J.
    Kush, D.
    Qin, Y.
    Li, B.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
  • [49] Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Lorena Incorvaia
    Daniele Fanale
    Giuseppe Badalamenti
    Nadia Barraco
    Marco Bono
    Lidia Rita Corsini
    Antonio Galvano
    Valerio Gristina
    Angela Listì
    Salvatore Vieni
    Stefania Gori
    Viviana Bazan
    Antonio Russo
    Advances in Therapy, 2019, 36 : 2600 - 2617
  • [50] Characterization of PD-L1 Expression Related to Unique Genes in NSCLC Tissue Samples
    Garon, Edward B.
    Mckenna, Robert
    Dering, Judy
    Wolf, Brian
    Pitts, Sharon
    Kamranpour, Naeimeh
    Chen, Hsiaowang
    Lisberg, Aaron
    Cameron, Robert B.
    Lee, Jay M.
    Dubinett, Steven M.
    Slamon, Dennis J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S198 - S198
12345